Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmanovia

Full company profile

uuid0007ogg

Namestring
Pharmanovia
Legal namestring
Atnahs Pharma UK Limited
Websiteurl
pharmanovia.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Pharmanovia is a global specialty pharmaceutical company headquartered in Basildon, UK, founded in 2013 by Dr. Amit Patel (originally as Atnahs, rebranded to Pharmanovia in 2021) and backed by private equity firm Triton since 2019. The company operates a two-pronged model: it manages a portfolio of more than 30 trusted established pharmaceutical brands (including Valium, Inderal, Zestril, Synacthen, Naprosyn, Famvir and Rocaltrol) across endocrinology, neurology, cardiovascular and oncology therapy areas, while simultaneously in-licensing and commercialising innovative specialty medicines such as Korjuny (catumaxomab) for malignant ascites, abaloparatide (TYMLOS) for osteoporosis, Sunosi for narcolepsy and obstructive sleep apnoea, GHRYVELIN for growth hormone deficiency diagnosis, and a diazepam buccal film using PharmFilm technology for seizure clusters. The pipeline includes six new chemical entities, with elamipretide for the ultra-rare Barth syndrome under regulatory progression following an MHRA Paediatric Investigational Plan submission in December 2024.

The company commercialises through a capital-light asset model, relying on Contract Manufacturing Organisations for production and a mix of Third-Party Logistics providers, local specialist distributors, Contract Sales Organisations and regional channel partners (such as Er-Kim in Eastern Europe and Echo Therapeutics in Australia) for distribution and promotion. It claims active presence in more than 160 markets with 13 offices across the UK (Basildon HQ plus a new London office), Germany, Netherlands, Belgium, Switzerland, Italy, Denmark, Turkey, the UAE (Dubai), Australia, India (Vadodara product development centre plus Mumbai), Singapore, South Korea, and the United States. Notable transactions include the 2023 acquisition of an 11-brand CNS portfolio from Sanofi, the November 2024 licensing of catumaxomab from Lindis Biotech (leading to a December 2025 Germany launch), and the January 2025 Asia Pacific in-licensing of abaloparatide from Radius Health.

Revenue is generated through a mix of one-time licensing transactions, licensing/royalties on in-licensed specialty assets, and product sales of established brands distributed through wholesalers and partners. The company does not publicly disclose pricing details, revenue figures, or detailed ownership percentages. With more than 300 specialists globally and a leadership team substantially refreshed in 2025-2026 (including CEO Stephan Eder from Stada), Pharmanovia positions itself as a mid-sized specialty pharma platform leveraging commercial infrastructure, regulatory expertise, and a disciplined BD/licensing/M&A framework to extend the lifecycle of established medicines and accelerate the launch of specialty assets across EMEA and APAC.

Short descriptiontext

Pharmanovia is a global specialty pharmaceutical company that in-licenses and commercialises innovative specialty medicines while lifecycle-managing more than 30 trusted established brands across endocrinology, neurology, cardiovascular and oncology, serving patients and healthcare providers in more than 160 markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBasildon, United Kingdom
HQ citystring
Basildon
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, pharmaceutical licensing, branded medicines, drug commercialization, established brands
Industry1 code
PRIMARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Commercialization of established brands
TypeOne Time License
Description

Pharmanovia revitalizes, extends and expands lifecycle of established medicines. They manage a broad portfolio of trusted established brands which provide important patient treatment options today across endocrine, neurological, cardiovascular and oncological conditions.

pharmanovia.com
2Specialty pharmaceutical products
TypeLicensing Royalties
Description

Bringing innovative specialty medicines to patients through acquisitions and licensing deals. Focus on launching and commercializing specialty pharma products in EMEA region with local execution rooted in insight and partnership.

pharmanovia.com
3New chemical entity licensing
TypeLicensing Royalties
Description

Identification and development of new chemical entities that complement existing portfolio to address unmet need. 6 NCEs in pipeline as of April 2026.

clinicaltrialvanguard.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 20 records shown
1Korjuny (catumaxomab)
Description

First-in-class treatment for malignant ascites, a rare and debilitating complication of advanced-stage cancer

pharmanovia.com
+19 more records
Core offering1 text field

Pharmanovia is a global specialty pharmaceutical company that acquires, revitalises and commercialises a portfolio of branded prescription medicines across more than 160 markets. The company operates two complementary engines: bringing innovative specialty medicines to market through in-licensing and acquisitions, and managing a broad portfolio of trusted established brands in endocrinology, neurology, cardiovascular and oncology. Manufacturing is outsourced to Contract Manufacturing Organisations (CMOs) and distribution is delivered via 3PLs and Contract Sales Organisations (CSOs).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Catumaxomab (Korjuny) reduces the need for invasive procedures (paracentesis) and improves quality of life for malignant ascites patients
+1 more record
Product overview1 text field

Pharmanovia is a global specialty pharmaceutical company focused on two main areas: innovative specialty medicines and trusted established brands. The specialty portfolio includes novel treatments like Korjuny (catumaxomab) for malignant ascites, abaloparatide for osteoporosis, cariprazine for schizophrenia, elamipretide for Barth syndrome, and diazepam buccal film for epilepsy. The established brands portfolio encompasses over 30 trusted brands across therapeutic areas including endocrinology, neurology, cardiovascular, and oncology. The company operates across more than 160 markets globally.

Product and service9 records
1Korjuny (catumaxomab)
CategorySpecialty medicine - Oncology
Description

First-in-class trifunctional T-cell engaging bispecific antibody for the treatment of malignant ascites in adults with EpCAM-positive carcinomas who are not eligible for systemic anticancer therapy; licensed from Lindis Biotech for Europe.

2Abaloparatide (TYMLOS)
CategorySpecialty medicine - Endocrinology
Description

Human parathyroid hormone related peptide analogue indicated for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; in-licensed from Radius Health for Asia Pacific.

3Reagila (cariprazine)
CategorySpecialty medicine - Neurology (CNS)
Description

Third-generation atypical antipsychotic indicated for the treatment of schizophrenia in adult patients; commercialised by Pharmanovia in Australia and New Zealand.

4Elamipretide
CategorySpecialty medicine - Rare disease (Investigational)
Description

Investigational mitochondrial protective agent being developed for the treatment of Barth syndrome, an ultra-rare mitochondrial disease; in-licensed from Stealth BioTherapeutics, with a Paediatric Investigational Plan submitted to the MHRA in December 2024.

5Diazepam Buccal Film (Libervant)
CategorySpecialty medicine - Neurology (Epilepsy)
Description

Patented diazepam buccal film using PharmFilm technology for acute treatment of intermittent stereotypic episodes of frequent seizure activity in epilepsy patients; in-licensed from Aquestive Therapeutics.

6Xadago (safinamide)
CategorySpecialty medicine - Neurology (CNS)
Description

Treatment for Parkinson's disease; acquired rights for Australia and New Zealand.

7Sunosi (solriamfetol)
CategorySpecialty medicine - Neurology (CNS)
Description

Treatment for wakefulness in patients with narcolepsy or obstructive sleep apnea; in-licensed from Axsome Therapeutics for EMEA, with Er-Kim as exclusive distributor in Eastern Europe.

8GHRYVELIN (macimorelin)
CategorySpecialty medicine - Endocrinology (Diagnostics)
Description

First and only orally administered approved medicine for the diagnosis of growth hormone deficiency in adults; in-licensed from Aeterna Zentaris.

9Established Brands Portfolio
CategoryEstablished brands - Lifecycle management
Description

Portfolio of more than 30 trusted established prescription medicines across endocrinology, neurology, cardiovascular and oncology therapeutic areas, including Dipentum, Anaprox, Naprosyn, Toradol, Bondronat, Bonviva, Kytril, Famvir, Synacthen, Inderal, Tenoretic, Tenormin, Zestoretic, Zestril, Rocaltrol, Valium and Leustatin; sourced via acquisitions from Roche, UCB, Novartis, AstraZeneca, J&J, Sanofi and Mallinckrodt.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-01
Description

CNX Therapeutics acquired Tacrolimus 5 mg/ml concentrate for solution for infusion from Pharmanovia on April 1, 2026. The product is used in hospital settings to prevent organ rejection in liver, kidney, and heart transplant patients. Commercial launch planned across Germany, France, Spain, with UK to follow.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-01
Description

Acquisition of rights to Reagila (cariprazine) from CSL Seqirus in Australia and New Zealand. Gedeon Richter remains Marketing Authorisation holder. Pharmanovia takes responsibility for commercial activity in the region.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-21
Description

Exclusive distribution agreement with Er-Kim for Sunosi in Eastern Europe.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-02
Description

Exclusive in-licensing agreement for abaloparatide (marketed as TYMLOS in US) for treatment of osteoporosis. Pharmanovia responsible for clinical, regulatory and commercial activities across key Asia Pacific markets including China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and the Philippines.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-19
Description

Partnership to commercialize catumaxomab (Korjuny), a first-in-class trifunctional bispecific monoclonal antibody for treatment of malignant ascites. Lindis granted Pharmanovia exclusive rights to bring catumaxomab to market and lead all activities to launch across Europe. Catumaxomab received European marketing authorisation approval in February 2025 and was launched in Germany in December 2025.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-05-20
Description

Agreement for promotional activities in Australia for Pharmanovia's Pain/CNS portfolio and selected products within the endocrinology portfolio. Echo Therapeutics conducts promotional activities while distribution and supply arrangements remain unchanged.

7IRDiRC (International Rare Disease Research Consortium)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

Pharmanovia joined IRDiRC task force to publish drug repurposing guidebook aimed at improving care for people living with rare disease. Guidebook published in Nature Reviews Drug Discovery. Task force committed to supporting 1,000 new therapies for rare diseases to be approved by 2027.

pharmanovia.com
8Stealth BioTherapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-30
Description

New chemical entity licensing agreement to market and further develop elamipretide, a potential novel treatment for Barth syndrome (ultra-rare mitochondrial disease). Pharmanovia submitted Paediatric Investigational Plan to MHRA in December 2024.

pharmanovia.com
9Aeterna Zentaris
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-22
Description

Exclusive licensing agreement for GHRYVELIN (macimorelin), the first and only orally administered approved medicine for diagnosis of growth hormone deficiency in adults.

pharmanovia.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Exclusive in-license agreement for Sunosi across Europe, Middle East and North America (MENA) regions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-01
Description

Expanded exclusive licence and supply agreement for patented diazepam buccal film formulation (Libervant) using PharmFilm technology. Initially for EU and MENA, expanded to include rest of world excluding US, Canada and China. For acute treatment of intermittent stereotypic episodes of frequent seizure activity in epilepsy patients.

Strategic tierMinorTypeOthersAnnounced on2022-01-01
Description

Partnership with global health NGO supporting people in disaster-hit and vulnerable communities to access vital medicines. During 2025, provided donations of critical medicines for Zanzibar to support ongoing cardiovascular care programme.

Strategic tierMinorTypeOthersAnnounced on2021-01-01
Description

Global charity partnership established in 2021 to help strengthen healthcare infrastructure in Zanzibar and improve access to essential medicines and treatment for underserved communities. Pharmanovia has helped train healthcare professionals, provide life-saving equipment and deliver critical medicines.

Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German specialty/generics pharma backed by Bain Capital and Cinven that acquires and revitalizes off-patent and specialty brands across Europe. Closest structural peer to Pharmanovia with similar asset-light European commercialization platform and PE-backed growth strategy.

TypeDirect peer
Description

Spanish specialty pharma focused on dermatology and specialty medicines with strong European commercialization capabilities. Comparable in business model emphasis on specialty pharma lifecycle management and geographic focus on Europe.

TypeDirect peer
Description

US specialty pharma focused on autoimmune and severe diseases with established brand management capabilities. Comparable in focus on specialty/established brand portfolio and lifecycle management of differentiated therapies.

TypeDirect peer
Description

Jordanian-headquartered specialty and generics pharma with significant presence in MENA, US, and Europe. Comparable in geographic diversification strategy, branded and specialty portfolio, and MEA commercial focus.

TypeBroad incumbent
Description

Global specialty/generics giant formed from Mylan and Pfizer's Upjohn. Comparable in established brand portfolio and global commercialization, but operates at materially larger scale across broader therapeutic areas.

TypeBroad incumbent
Description

Global specialty and generics leader with extensive CNS franchise including therapeutic areas overlapping with Pharmanovia's portfolio (e.g., schizophrenia, Parkinson's). Operates at vastly larger scale across broader geographies.

TypeDirect peer
Description

Indian specialty generics pharma with global commercial presence including Europe and emerging markets. Comparable in specialty brand lifecycle management and global out-licensing/in-licensing activity.

TypeDirect peer
Description

South African specialty and branded generics pharma with global reach including Europe and emerging markets. Comparable model of acquiring and commercializing brands divested by multinational pharma across multiple geographies.

TypeDirect peer
Description

Japanese specialty pharma with strong rare disease and biologics pipeline. Comparable in niche specialty focus, biologics like catumaxomab, and in-licensing model for assets outside core geographies.

TypeDirect peer
Description

Italian specialty pharma with leading rare disease franchise and established European commercialization. Comparable in therapeutic breadth (cardiology, urology, rare diseases) and specialty pharma focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmanovia

Specialty Pharmaceuticalspharmanovia.com

Pharmanovia is a global specialty pharmaceutical company that in-licenses and commercialises innovative specialty medicines while lifecycle-managing more than 30 trusted established brands across endocrinology, neurology, cardiovascular and oncology, serving patients and healthcare providers in more than 160 markets.

What Pharmanovia does

Pharmanovia is a global specialty pharmaceutical company headquartered in Basildon, UK, founded in 2013 by Dr. Amit Patel (originally as Atnahs, rebranded to Pharmanovia in 2021) and backed by private equity firm Triton since 2019. The company operates a two-pronged model: it manages a portfolio of more than 30 trusted established pharmaceutical brands (including Valium, Inderal, Zestril, Synacthen, Naprosyn, Famvir and Rocaltrol) across endocrinology, neurology, cardiovascular and oncology therapy areas, while simultaneously in-licensing and commercialising innovative specialty medicines such as Korjuny (catumaxomab) for malignant ascites, abaloparatide (TYMLOS) for osteoporosis, Sunosi for narcolepsy and obstructive sleep apnoea, GHRYVELIN for growth hormone deficiency diagnosis, and a diazepam buccal film using PharmFilm technology for seizure clusters. The pipeline includes six new chemical entities, with elamipretide for the ultra-rare Barth syndrome under regulatory progression following an MHRA Paediatric Investigational Plan submission in December 2024.

The company commercialises through a capital-light asset model, relying on Contract Manufacturing Organisations for production and a mix of Third-Party Logistics providers, local specialist distributors, Contract Sales Organisations and regional channel partners (such as Er-Kim in Eastern Europe and Echo Therapeutics in Australia) for distribution and promotion. It claims active presence in more than 160 markets with 13 offices across the UK (Basildon HQ plus a new London office), Germany, Netherlands, Belgium, Switzerland, Italy, Denmark, Turkey, the UAE (Dubai), Australia, India (Vadodara product development centre plus Mumbai), Singapore, South Korea, and the United States. Notable transactions include the 2023 acquisition of an 11-brand CNS portfolio from Sanofi, the November 2024 licensing of catumaxomab from Lindis Biotech (leading to a December 2025 Germany launch), and the January 2025 Asia Pacific in-licensing of abaloparatide from Radius Health.

Revenue is generated through a mix of one-time licensing transactions, licensing/royalties on in-licensed specialty assets, and product sales of established brands distributed through wholesalers and partners. The company does not publicly disclose pricing details, revenue figures, or detailed ownership percentages. With more than 300 specialists globally and a leadership team substantially refreshed in 2025-2026 (including CEO Stephan Eder from Stada), Pharmanovia positions itself as a mid-sized specialty pharma platform leveraging commercial infrastructure, regulatory expertise, and a disciplined BD/licensing/M&A framework to extend the lifecycle of established medicines and accelerate the launch of specialty assets across EMEA and APAC.

Pharmanovia firmographics

Firmographics
Name
Pharmanovia
Legal name
Atnahs Pharma UK Limited
Website
https://pharmanovia.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
251–500 employees
Short description
Pharmanovia is a global specialty pharmaceutical company that in-licenses and commercialises innovative specialty medicines while lifecycle-managing more than 30 trusted established brands across endocrinology, neurology, cardiovascular and oncology, serving patients and healthcare providers in more than 160 markets.
Ownership category
akta.pro rank

Pharmanovia industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences

Keywords

  • Specialty pharmaceuticals
  • Pharmaceutical licensing
  • Branded medicines
  • Drug commercialization
  • Established brands

Where Pharmanovia is headquartered

Location

Headquarters

HQ city
Basildon
HQ country
United Kingdom
HQ region
Europe

Offices8 records

Markets served

Pharmanovia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

  1. Commercialization of established brands: Pharmanovia revitalizes, extends and expands lifecycle of established medicines. They manage a broad portfolio of trusted established brands which provide important patient treatment options today across endocrine, neurological, cardiovascular and oncological conditions.
  2. Specialty pharmaceutical products: Bringing innovative specialty medicines to patients through acquisitions and licensing deals. Focus on launching and commercializing specialty pharma products in EMEA region with local execution rooted in insight and partnership.
  3. New chemical entity licensing: Identification and development of new chemical entities that complement existing portfolio to address unmet need. 6 NCEs in pipeline as of April 2026.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Pharmanovia product offering

Product offering

Core offering

Pharmanovia is a global specialty pharmaceutical company that acquires, revitalises and commercialises a portfolio of branded prescription medicines across more than 160 markets. The company operates two complementary engines: bringing innovative specialty medicines to market through in-licensing and acquisitions, and managing a broad portfolio of trusted established brands in endocrinology, neurology, cardiovascular and oncology. Manufacturing is outsourced to Contract Manufacturing Organisations (CMOs) and distribution is delivered via 3PLs and Contract Sales Organisations (CSOs).

Product overview

Pharmanovia is a global specialty pharmaceutical company focused on two main areas: innovative specialty medicines and trusted established brands. The specialty portfolio includes novel treatments like Korjuny (catumaxomab) for malignant ascites, abaloparatide for osteoporosis, cariprazine for schizophrenia, elamipretide for Barth syndrome, and diazepam buccal film for epilepsy. The established brands portfolio encompasses over 30 trusted brands across therapeutic areas including endocrinology, neurology, cardiovascular, and oncology. The company operates across more than 160 markets globally.

Differentiator

Problem solved

Functional benefit

Brands

  • Korjuny (catumaxomab): First-in-class treatment for malignant ascites, a rare and debilitating complication of advanced-stage cancer
  • TYMLOS (abaloparatide)
  • Sunosi
  • GHRYVELIN (macimorelin)
  • Xadago
  • Reagila (cariprazine)
  • Valium
  • Diazepam Buccal Film
  • Synacthen
  • Inderal
  • Rocaltrol
  • Bonviva
  • Kytril
  • Bondronat
  • Dipentum
  • Naprosyn
  • Anaprox
  • Toradol
  • Famvir
  • Leustatin

Products and services

  • Korjuny (catumaxomab) First-in-class trifunctional T-cell engaging bispecific antibody for the treatment of malignant ascites in adults with EpCAM-positive carcinomas who are not eligible for systemic anticancer therapy; licensed from Lindis Biotech for Europe.
  • Abaloparatide (TYMLOS) Human parathyroid hormone related peptide analogue indicated for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; in-licensed from Radius Health for Asia Pacific.
  • Reagila (cariprazine) Third-generation atypical antipsychotic indicated for the treatment of schizophrenia in adult patients; commercialised by Pharmanovia in Australia and New Zealand.
  • Elamipretide Investigational mitochondrial protective agent being developed for the treatment of Barth syndrome, an ultra-rare mitochondrial disease; in-licensed from Stealth BioTherapeutics, with a Paediatric Investigational Plan submitted to the MHRA in December 2024.
  • Diazepam Buccal Film (Libervant) Patented diazepam buccal film using PharmFilm technology for acute treatment of intermittent stereotypic episodes of frequent seizure activity in epilepsy patients; in-licensed from Aquestive Therapeutics.
  • Xadago (safinamide) Treatment for Parkinson's disease; acquired rights for Australia and New Zealand.
  • Sunosi (solriamfetol) Treatment for wakefulness in patients with narcolepsy or obstructive sleep apnea; in-licensed from Axsome Therapeutics for EMEA, with Er-Kim as exclusive distributor in Eastern Europe.
  • GHRYVELIN (macimorelin) First and only orally administered approved medicine for the diagnosis of growth hormone deficiency in adults; in-licensed from Aeterna Zentaris.
  • Established Brands Portfolio Portfolio of more than 30 trusted established prescription medicines across endocrinology, neurology, cardiovascular and oncology therapeutic areas, including Dipentum, Anaprox, Naprosyn, Toradol, Bondronat, Bonviva, Kytril, Famvir, Synacthen, Inderal, Tenoretic, Tenormin, Zestoretic, Zestril, Rocaltrol, Valium and Leustatin; sourced via acquisitions from Roche, UCB, Novartis, AstraZeneca, J&J, Sanofi and Mallinckrodt.

Quantifiable outcome

  • Catumaxomab (Korjuny) reduces the need for invasive procedures (paracentesis) and improves quality of life for malignant ascites patients
  • +1 more outcomes

Companies that use Pharmanovia

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Pharmanovia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Pharmanovia partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered minor and core.

  • CNX TherapeuticsminorChannel Partner/ Reseller/ Distributor · 1 April 2026CNX Therapeutics acquired Tacrolimus 5 mg/ml concentrate for solution for infusion from Pharmanovia on April 1, 2026. The product is used in hospital settings to prevent organ rejection in liver, kidney, and heart transplant patients. Commercial launch planned across Germany, France, Spain, with UK to follow.
  • CSL SeqirusminorChannel Partner/ Reseller/ Distributor · 1 April 2025Acquisition of rights to Reagila (cariprazine) from CSL Seqirus in Australia and New Zealand. Gedeon Richter remains Marketing Authorisation holder. Pharmanovia takes responsibility for commercial activity in the region.
  • Er-KimminorChannel Partner/ Reseller/ Distributor · 21 February 2025Exclusive distribution agreement with Er-Kim for Sunosi in Eastern Europe.
  • Radius HealthcoreStrategic or Co-development Partner · 2 January 2025Exclusive in-licensing agreement for abaloparatide (marketed as TYMLOS in US) for treatment of osteoporosis. Pharmanovia responsible for clinical, regulatory and commercial activities across key Asia Pacific markets including China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and the Philippines.
  • Lindis BiotechcoreStrategic or Co-development Partner · 19 November 2024Partnership to commercialize catumaxomab (Korjuny), a first-in-class trifunctional bispecific monoclonal antibody for treatment of malignant ascites. Lindis granted Pharmanovia exclusive rights to bring catumaxomab to market and lead all activities to launch across Europe. Catumaxomab received European marketing authorisation approval in February 2025 and was launched in Germany in December 2025.
  • Echo TherapeuticsminorChannel Partner/ Reseller/ Distributor · 20 May 2024Agreement for promotional activities in Australia for Pharmanovia's Pain/CNS portfolio and selected products within the endocrinology portfolio. Echo Therapeutics conducts promotional activities while distribution and supply arrangements remain unchanged.
  • IRDiRC (International Rare Disease Research Consortium)minorStrategic or Co-development Partner · 1 November 2023Pharmanovia joined IRDiRC task force to publish drug repurposing guidebook aimed at improving care for people living with rare disease. Guidebook published in Nature Reviews Drug Discovery. Task force committed to supporting 1,000 new therapies for rare diseases to be approved by 2027.
  • Stealth BioTherapeuticscoreStrategic or Co-development Partner · 30 May 2023New chemical entity licensing agreement to market and further develop elamipretide, a potential novel treatment for Barth syndrome (ultra-rare mitochondrial disease). Pharmanovia submitted Paediatric Investigational Plan to MHRA in December 2024.
  • Aeterna ZentariscoreStrategic or Co-development Partner · 22 March 2023Exclusive licensing agreement for GHRYVELIN (macimorelin), the first and only orally administered approved medicine for diagnosis of growth hormone deficiency in adults.
  • Axsome TherapeuticscoreStrategic or Co-development Partner · 1 January 2023Exclusive in-license agreement for Sunosi across Europe, Middle East and North America (MENA) regions.
  • Aquestive TherapeuticscoreStrategic or Co-development Partner · 1 September 2022Expanded exclusive licence and supply agreement for patented diazepam buccal film formulation (Libervant) using PharmFilm technology. Initially for EU and MENA, expanded to include rest of world excluding US, Canada and China. For acute treatment of intermittent stereotypic episodes of frequent seizure activity in epilepsy patients.
  • International Health Partners (IHP)minorOthers · 1 January 2022Partnership with global health NGO supporting people in disaster-hit and vulnerable communities to access vital medicines. During 2025, provided donations of critical medicines for Zanzibar to support ongoing cardiovascular care programme.
  • HIPZ (Health Improvement Programme Zanzibar)minorOthers · 1 January 2021Global charity partnership established in 2021 to help strengthen healthcare infrastructure in Zanzibar and improve access to essential medicines and treatment for underserved communities. Pharmanovia has helped train healthcare professionals, provide life-saving equipment and deliver critical medicines.

Scale indicators9 records

Recent moves13 records

Expansion highlights6 records

Pharmanovia competitors and assessment

Company assessment

Direct peers

  • STADA Arzneimittel: German specialty/generics pharma backed by Bain Capital and Cinven that acquires and revitalizes off-patent and specialty brands across Europe. Closest structural peer to Pharmanovia with similar asset-light European commercialization platform and PE-backed growth strategy.
  • Almirall: Spanish specialty pharma focused on dermatology and specialty medicines with strong European commercialization capabilities. Comparable in business model emphasis on specialty pharma lifecycle management and geographic focus on Europe.
  • Mallinckrodt: US specialty pharma focused on autoimmune and severe diseases with established brand management capabilities. Comparable in focus on specialty/established brand portfolio and lifecycle management of differentiated therapies.
  • Hikma Pharmaceuticals: Jordanian-headquartered specialty and generics pharma with significant presence in MENA, US, and Europe. Comparable in geographic diversification strategy, branded and specialty portfolio, and MEA commercial focus.
  • Lupin: Indian specialty generics pharma with global commercial presence including Europe and emerging markets. Comparable in specialty brand lifecycle management and global out-licensing/in-licensing activity.
  • Aspen Pharmacare: South African specialty and branded generics pharma with global reach including Europe and emerging markets. Comparable model of acquiring and commercializing brands divested by multinational pharma across multiple geographies.
  • Kyowa Kirin: Japanese specialty pharma with strong rare disease and biologics pipeline. Comparable in niche specialty focus, biologics like catumaxomab, and in-licensing model for assets outside core geographies.
  • Recordati: Italian specialty pharma with leading rare disease franchise and established European commercialization. Comparable in therapeutic breadth (cardiology, urology, rare diseases) and specialty pharma focus.

Broad incumbents

  • Viatris: Global specialty/generics giant formed from Mylan and Pfizer's Upjohn. Comparable in established brand portfolio and global commercialization, but operates at materially larger scale across broader therapeutic areas.
  • Teva Pharmaceutical: Global specialty and generics leader with extensive CNS franchise including therapeutic areas overlapping with Pharmanovia's portfolio (e.g., schizophrenia, Parkinson's). Operates at vastly larger scale across broader geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Pharmanovia social profiles

Digital presence

Pharmanovia compliance and trust

Trust signal

Compliance4 records

Pharmanovia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmanovia leadership team

Management profile

Number of profiles

Profiles15 records

Pharmanovia subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Pharmanovia funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmanovia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmanovia

What does Pharmanovia do?

Pharmanovia is a global specialty pharmaceutical company that acquires, revitalises and commercialises a portfolio of branded prescription medicines across more than 160 markets. The company operates two complementary engines: bringing innovative specialty medicines to market through in-licensing and acquisitions, and managing a broad portfolio of trusted established brands in endocrinology, neurology, cardiovascular and oncology. Manufacturing is outsourced to Contract Manufacturing Organisations (CMOs) and distribution is delivered via 3PLs and Contract Sales Organisations (CSOs).

Is Pharmanovia a public or private company?

Pharmanovia is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pharmanovia founded?

Pharmanovia was founded in 2013. It employs 251 to 500 people.

Where is Pharmanovia based?

Pharmanovia is headquartered in Basildon, United Kingdom, in the Europe region.

How does Pharmanovia make money?

Three revenue lines are on record. Commercialization of established brands are the primary driver. The others are specialty pharmaceutical products and new chemical entity licensing.

Who are Pharmanovia's main competitors?

Direct peers on record are STADA Arzneimittel, Almirall, Mallinckrodt, Hikma Pharmaceuticals, Lupin, Aspen Pharmacare, Kyowa Kirin and Recordati. Broad incumbents are Viatris and Teva Pharmaceutical.

Does Pharmanovia have an API?

No public API is recorded for Pharmanovia.

What industry is Pharmanovia in?

Pharmanovia's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MoomooEU approval for senaparib marks a critical step toward global commercialization, accelerating the realization of its innovative value and making Impmed Biopharma-B (07630) a key investment holding.InnoCare Pharma announced EU approval of its PARP inhibitor senaparib for maintenance therapy in advanced ovarian, fallopian tube, and peritoneal cancers. The drug, approved in China last January, is now available in multiple regions, and the company licensed it to Pharmanovia for global commercialization. The approval marks a key step toward global commercialization and stable recurring cash flow.AInvestThe HSCI Isn't a Trophy — It's a Liquidity PipeIMPACT Therapeutics is set to join the Hang Seng Composite Index on September 7, unlocking eligibility for mainland Chinese investors via the Southbound Stock Connect program. This inclusion provides critical liquidity support for the Hong Kong-listed biotech, which has lost 70% of its market value and faces significant annual losses despite securing a major licensing deal with Pharmanovia.YahooIMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparibChina-based IMPACT Therapeutics has granted Pharmanovia exclusive licensing rights worth up to $488.3 million for senaparib, a PARP1/2 inhibitor for ovarian cancer maintenance therapy, covering 66 countries including all EU member states, the UK, Australia, and New Zealand. Under the agreement, IMPACT Therapeutics will receive an upfront payment, regulatory and commercial milestones, and tiered royalties up to the mid-twenties percentage on net sales. The partnership aims to accelerate senaparib's availability following regulatory approvals, with the European Medicines Agency expected to issue a decision in the second half of 2026.Pharmaceutical TechnologyIMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparibChina-based IMPACT Therapeutics has granted Pharmanovia exclusive licensing rights to senaparib, a PARP1/2 inhibitor for ovarian cancer maintenance therapy, in a deal worth up to €423.5m ($488.3m). The agreement covers 66 countries including all EU member states, the UK, Australia, New Zealand, Switzerland, Norway, and Middle East/North Africa territories, with IMPACT receiving upfront payment, regulatory and commercial milestones, and tiered royalties up to the mid-twenties percent on net sales. Senaparib received approval from China's National Medical Products Administration in January 2025 and was added to China's National Reimbursement Drug List in December 2025, while the European Medicines Agency accepted a marketing authorisation application in August 2025 with a decision expected in H2 2026.PR NewswireIMPACT Therapeutics firma un acuerdo de licencia exclusiva con PharmanoviaIMPACT Therapeutics announced an exclusive license agreement with Pharmanovia granting exclusive rights to manufacture, develop, and commercialize senaparib (a PARP1/2 inhibitor) in Europe, the Middle East, North Africa, Australia, and New Zealand for maintenance therapy of advanced high-grade ovarian cancer. Under the deal, IMPACT is eligible to receive up to €423.5 million in upfront, regulatory, and commercial milestone payments, plus tiered royalties up to 25% on net sales. The agreement expands senaparib's global reach to 66 countries, with the EMA having accepted the marketing authorization application in August 2025 and approval expected in the second half of 2026.PR NewswireIMPACT Therapeutics unterzeichnet Exklusivlizenzvertrag mit Pharmanovia für Senaparib in Europa, dem Nahen Osten und Nordafrika, Australien und NeuseelandIMPACT Therapeutics (07630.HK) has granted Pharmanovia exclusive rights to manufacture, develop, and market Senaparib — its PARP1/2 inhibitor for advanced ovarian cancer — in Europe, the Middle East, North Africa, Australia, and New Zealand. Under the deal, IMPACT is entitled to an upfront payment, regulatory and commercial milestone payments totaling up to €423.5 million, plus tiered royalties of up to the mid-twenties percent on net sales. The EMA accepted Senaparib's Marketing Authorization Application in August 2025, with approval expected in the second half of 2026, and this partnership extends Senaparib's geographic reach to 66 countries as IMPACT's first step to making the drug available to patients outside China.PR NewswireIMPACT Therapeutics signe un accord de licence exclusif avec Pharmanovia concernant le sénaparib en Europe, au Moyen-Orient et en Afrique du Nord, ainsi qu'en Australie et en Nouvelle-ZélandeIMPACT Therapeutics has granted Pharmanovia exclusive rights to manufacture, develop, and commercialize senaparib for maintenance treatment of advanced ovarian cancer across Europe, the Middle East, North Africa, Australia, and New Zealand, extending the drug's global reach to 66 countries. Under the terms of the exclusive licensing agreement, IMPACT is eligible to receive up to €423.5 million in upfront and milestone payments plus tiered royalties of up to approximately 25% of net product sales. The EMA formally accepted the senaparib marketing authorization application in August 2025, with approval expected in the second half of 2026, marking IMPACT's first step toward making its validated therapeutic options available to patients outside China.